<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Spargias, K</style></author><author><style face="normal" font="default" size="100%">Adreanides, E</style></author><author><style face="normal" font="default" size="100%">Giamouzis, G</style></author><author><style face="normal" font="default" size="100%">Karagiannis, S.</style></author><author><style face="normal" font="default" size="100%">Gouziouta, A</style></author><author><style face="normal" font="default" size="100%">Manginas, A.</style></author><author><style face="normal" font="default" size="100%">Voudris, V</style></author><author><style face="normal" font="default" size="100%">Pavlides, Gregory</style></author><author><style face="normal" font="default" size="100%">Cokkinos, D.V.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Iloprost for prevention of contrast-mediated nephropathy in high-risk patients undergoing a coronary procedure. Results of a randomized pilot study</style></title><secondary-title><style face="normal" font="default" size="100%">European journal of clinical pharmacology</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year></dates><number><style face="normal" font="default" size="100%">8</style></number><publisher><style face="normal" font="default" size="100%">Springer-Verlag</style></publisher><volume><style face="normal" font="default" size="100%">62</style></volume><pages><style face="normal" font="default" size="100%">589–595</style></pages><language><style face="normal" font="default" size="100%">eng</style></language></record></records></xml>